Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Chubb
Covington
Medtronic
Dow
Healthtrust
Teva
UBS
Fuji
Baxter

Generated: October 18, 2017

DrugPatentWatch Database Preview

Novartis Pharms Corp Company Profile

« Back to Dashboard

What is the competitive landscape for NOVARTIS PHARMS CORP, and when can generic versions of NOVARTIS PHARMS CORP drugs launch?

NOVARTIS PHARMS CORP has sixty-eight approved drugs.

There are one hundred and nineteen US patents protecting NOVARTIS PHARMS CORP drugs and there have been six Paragraph IV challenges on NOVARTIS PHARMS CORP drugs in the past three years.

There are one thousand eight hundred and nineteen patent family members on NOVARTIS PHARMS CORP drugs in seventy-two countries and one hundred and sixty supplementary protection certificates in fifteen countries.

Summary for Applicant: Novartis Pharms Corp

International Patents:1819
US Patents:119
Tradenames:58
Ingredients:49
NDAs:68
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp
MEKINIST
trametinib dimethyl sulfoxide
TABLET;ORAL204114-003May 29, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Novartis Pharms Corp
ZYKADIA
ceritinib
CAPSULE;ORAL205755-001Apr 29, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Novartis Pharms Corp
PROMACTA
eltrombopag olamine
TABLET;ORAL022291-005Nov 16, 2012RXYesYes► Subscribe► SubscribeY► Subscribe
Novartis Pharms Corp
JADENU
deferasirox
TABLET;ORAL206910-001Mar 30, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Novartis Pharms Corp
PATANASE
olopatadine hydrochloride
SPRAY, METERED;NASAL021861-001Apr 15, 2008ABRXYesYes► Subscribe► SubscribeY► Subscribe
Novartis Pharms Corp
PROMACTA
eltrombopag olamine
TABLET;ORAL022291-004Oct 20, 2011RXYesNo► Subscribe► SubscribeY► Subscribe
Novartis Pharms Corp
ISOPTO ATROPINE
atropine sulfate
SOLUTION/DROPS;OPHTHALMIC208151-001Dec 1, 2016RXNoNo► Subscribe► Subscribe► Subscribe
Novartis Pharms Corp
VOTRIENT
pazopanib hydrochloride
TABLET;ORAL022465-002Oct 19, 2009DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Novartis Pharms Corp
VOTRIENT
pazopanib hydrochloride
TABLET;ORAL022465-002Oct 19, 2009DISCNNoNo► Subscribe► Subscribe► Subscribe
Novartis Pharms Corp
ENTRESTO
sacubitril; valsartan
TABLET;ORAL207620-003Jul 7, 2015RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Novartis Pharms Corp

Paragraph IV activity for NOVARTIS PHARMS CORP drugs

Drugname Dosage Strength Tradename Submissiondate
deferasirox
Tablets180 mg
JADENU
4/28/2016
travoprost
Ophthalmic Solution0.003%
IZBA
12/30/2015
nepafenac
Ophthalmic Suspension0.3%
ILEVRO
12/21/2015
deferasirox
Tablets180 mg
JADENU
10/23/2015
deferasirox
Tablets90 mg and 360 mg
JADENU
10/19/2015
olopatadine hydrochloride
Ophthalmic Solution0.7%
PAZEO
9/10/2015
difluprednate
Ophthalmic Emulsion0.05%
DUREZOL
5/1/2014
eltrombopag olamine
Tablets12.5 mg and 25 mg
PROMACTA
2/4/2014
eltrombopag olamine
Tablets50 mg and 75 mg
PROMACTA
1/7/2014
ciprofloxacin and dexamethasone
Otic Suspension0.3%/0.1%
CIPRODEX
7/31/2012
moxifloxacin hydrochloride
Ophthalmic Solution10.5%
MOXEZA
2/29/2012
argatroban in sodium chloride
Injection1 mg/mL, 50 mL vials
ARGATROBAN
12/16/2011
lapatinib ditosylate
Tablets250 mg
TYKERB
3/14/2011
olopatadine hydrochloride
Nasal Spray0.665 mg/ Spray
PATANASE
6/29/2009
travoprost (preserved)
Ophthalmic Solution0.00%
TRAVATAN Z
2/19/2009
olopatadine hydrochloride
Ophthalmic Solution0.20%
PATADAY
9/8/2008
argatroban
Injection100 mg/mL, 2.5 mL vials
ARGATROBAN
9/24/2007
olopatadine hydrochloride
Ophthalmic Solution0.10%
PATANOL
7/17/2006
moxifloxacin hydrochloride
Ophthalmic0.50%
VIGAMOX
12/22/2005
ondansetron hydrochloride
Oral Solution4 mg/5 mL
ZOFRAN
12/20/2004

Non-Orange Book Patents for Novartis Pharms Corp

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,825,116N2, N4-bis-aryl-5-fluoro-2,4-pyrimidinediamines► Subscribe
8,557,806Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds► Subscribe
7,754,733Crystalline topotecan hydrochloride product and process for making the same► Subscribe
6,486,138 Ophthalmic compositions containing galactomannan polymers and borate► Subscribe
8,334,2962,4-pyrimidinediamine compounds and their uses► Subscribe
9,346,7652,4-pyrimidinediamine compounds and their uses► Subscribe
7,858,626Pyrimidineamines as angiogenesis modulators► Subscribe
9,499,4932,4-pyrimidinediamine compounds and their uses► Subscribe
7,812,029Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds► Subscribe
7,557,2102,4-pyrimidinediamine compounds and their uses► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Novartis Pharms Corp Drugs

Country Document Number Estimated Expiration
Austria497495► Subscribe
Portugal1660458► Subscribe
BrazilPI0722384► Subscribe
Colombia6341561► Subscribe
Spain2550942► Subscribe
Denmark0999825► Subscribe
MexicoPA03001832► Subscribe
China1200926► Subscribe
TaiwanI544927► Subscribe
Portugal2298768► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Novartis Pharms Corp Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2014039,C1761528Lithuania► SubscribePRODUCT NAME: TRAMETINIBAS; REGISTRATION NO/DATE: EU/1/14/931/01-06 20140630
C/GB03/004United Kingdom► SubscribePRODUCT NAME: BRINZOLAMIDE; REGISTERED: CH IKS 55236 19991217; UK EU/1/00/129/01 20000309; UK EU/1/00/129/02 20000309
C/GB12/058United Kingdom► SubscribePRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
2015 00026Denmark► SubscribePRODUCT NAME: PASIREOTID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF ELLER ET HVILKET SOM HELST HYDRAT DERAF, HERUNDER PASIREOTIDDIASPARTAT; REG. NO/DATE: EU/1/12/753, C(2014)8916 20141121
C0049France► SubscribePRODUCT NAME: DEFERASIROX OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE IN FRANCE: EU/1/06/356/001 DU 20060828; REGISTRATION NO/DATE AT EEC: EU/1/06/356/001 DU 20060828
2004012Lithuania► SubscribePRODUCT NAME: MOXIFLOXACINI HYDROCHLORIDUM (1-CIKLOPROPIL-6-FLUOR-__ 1,4-DIHIDRO-8-METOKSI-7-[(4AS, 7AS)-OKTAHIDRO-6H-PIROLO[3,4-B]PIRIDIN_-6-IL]-4-OKSO-3-CHINOLINKARBOKSIRûGðTIES HIDROCHLORIDAS)
00671Netherlands► SubscribePRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EG EU/1/01/199/001-002 20011128
2013000085Germany► SubscribePRODUCT NAME: NEPAFENAC (OPHTHALMISCHE SUSPENSION); REGISTRATION NO/DATE: EU 1/07/433/002 20130503
1343782/01Switzerland► SubscribeFORMER OWNER: GLAXOSMITHKLINE LLC, US
90022-1Sweden► SubscribePRODUCT NAME: PASIREOTID; REG. NO/DATE: EU/1/12/753/001 20120424
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Federal Trade Commission
McKesson
Fish and Richardson
Merck
Johnson and Johnson
Harvard Business School
Deloitte
Baxter
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot